OncoLab Co., Ltd. visited Professor Andrew Lyon's research laboratory in the United States in January 2025 to discuss the synthesis and scale-up strategy for nanogel production within the ANGel platform. The primary objectives of this visit were to validate key technologies for pilot-scale production and to gain practical experience for the establishment of a 5L reactor.

The research team successfully synthesized nanogels using a 5L reactor, completing two production batches that met quality control (QC) standards. The final product maintained a particle size of 800 nm with a polydispersity index (PDI < 0.1)

Through this research collaboration, OncoLab has gained valuable hands-on experience in establishing a production process that complies with GLP/GMP standards. Based on these insights, the company plans to implement a 5L reactor and transition to large-scale production.

OncoLab remains committed to continuous research collaboration and technological advancements to develop an innovative platform that bridges the gap between immunotherapy and precision drug delivery.